p53-based therapeutics for head and neck squamous cell carcinoma.

p53-based therapeutics for head and neck squamous cell carcinoma.
复制标题

DOI:
10.1016/j.oraloncology.2013.03.447
复制
发表时间:
2013-08
期刊:
影响因子:
4.8
通讯作者:
Pan, Quintin
Pan, Quintin
中科院分区:
医学2区
文献类型:
--
作者:
Tassone, Patrick;Old, Matthew;Teknos, Theodoros N.;Pan, Quintin

文献摘要

参考文献

被引文献

相似文献

抑癌基因p53的失活是头颈部鳞状细胞癌(HNSCC)发展过程中的一个致病事件。在不存在功能性野生型p53的情况下,HNSCC细胞对标准化疗剂和放射具有增加的抗性。在过去的几十年中,已经开发了许多恢复癌细胞中p53功能的方法。这篇综述文章的重点是病毒的方法来提供野生型p53的HNSCC细胞,设计师的病毒,选择性地消除突变的p53 HNSCC细胞,和化学方法来重新激活p53在HNSCC细胞的功能。这些有希望的研究提供了证据,证明p53治疗剂可单独或与常规化疗和/或放疗联合用于HNSCC患者的管理。
Inactivation of the tumor suppressor p53 is a pathogenetic event in the development of head and neck squamous cell carcinoma (HNSCC). In the absence of functional wildtype p53, HNSCC cells have increased resistance to standard chemotherapeutics and radiation. Numerous approaches to restore p53 function in cancer cells have been developed over the past several decades. This review article focuses on viral approaches to deliver wildtype p53 to HNSCC cells, a designer virus that selectively eliminates mutant p53 HNSCC cells, and chemical approaches to reactivate p53 function in HNSCC cells. These promising studies provide evidence that p53 therapeutics may prove useful alone or in combination with conventional chemotherapy and/or radiation for the management of HNSCC patients.
DOI: 10.1002/humu.10081
发表时间: 2002-01-01
期刊: HUMAN MUTATION
影响因子: 3.9
作者:
Olivier, M;Eeles, R;Hainaut, P
通讯作者: Hainaut, P
DOI: 10.1200/jco.1998.16.6.2221
发表时间: 1998-06-01
影响因子: 45.3
作者:
Clayman, GL;El-Naggar, AK;Goepfert, H
通讯作者: Goepfert, H
DOI: 10.1016/0092-8674(93)90384-3
发表时间: 1993-11-05
期刊: CELL
影响因子: 64.5
作者:
SCHEFFNER, M;HUIBREGTSE, JM;HOWLEY, PM
通讯作者: HOWLEY, PM
DOI: 10.1056/nejmoa073770
发表时间: 2007-12-20
影响因子: 158.5
作者:
Poeta, M. Luana;Manola, Judith;Koch, Wayne M.
通讯作者: Koch, Wayne M.
DOI: 10.1158/1535-7163.mct-04-0206
发表时间: 2005-06-01
影响因子: 5.7
作者:
Li, Y;Mao, Y;Fine, RL
通讯作者: Fine, RL